bioRxivCancer BiologyPreprint
Integrated computational and experimental identification of p53, KRAS and VHL mutant selection associated with CRISPR-Cas9 editing
S. Sinha, K. O. Barbosa, K. Cheng, M. D. Leiserson, D. M. Wilson, B. M. Ryan, Z. A. Ronai, J. S. Lee, A. Deshpande, E. Ruppin
Abstract
Recent studies have reported that CRISPR-Cas9 gene editing induces a p53-dependent DNA damage response in primary cells, which may select for cells with oncogenic p53 mutations11,12. It is unclear whether these CRISPR-induced changes are applicable to different cell types, and whether CRISPR gene editing may select for other oncogenic mutations. Addressing these questions, we analyzed genome-wide CRISPR and RNAi screens to systematically chart the mutation selection potential of CRISPR knockouts across the whole exome. Our analysis suggests that CRISPR gene editing can select for mutants of KRAS and VHL, at a level comparable to that reported for p53. These predictions were further validated in a genome-wide manner by analyzing independent CRISPR screens and patients tumor data. Finally, we performed a new set of pooled and arrayed CRISPR screens to evaluate the competition between CRISPR-edited isogenic p53 WT and mutant cell lines, which further validated our predictions. In summary, our study systematically charts and points to the potential selection of specific cancer driver mutations during CRISPR-Cas9 gene editing.
- organism: human
- assay: whole-exome sequencing
- research focus: variant calling
- research focus: variant effect prediction
- approach: statistical model
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- TP53-dependent CRISPR-Cas9 sex bias across cancer types affects MYC, PIK3CA, and SUV39H1 mediated by factors including SOX9, FOXO4, and PRC1
Mengbiao Guo, Yuanyan Xiong·bioRxiv·Aug 3, 2022
- CRISPR enriches for cells with mutations in a p53-related interactome, and this can be inhibited.
L. Jiang, K. Ingelshed, … F. Wermeling·bioRxiv·Mar 10, 2021
- Selective targeting of an oncogenic KRAS mutant allele by CRISPR/Cas9 induces efficient tumor regression
Qianqian Gao, Wenjie Ouyang, … Cheng‐Chi Chao·TheranosticsPeer-reviewed·Jan 1, 2020
- Parallel CRISPR-Cas9 screens clarify impacts of p53 on screen performance
Anne Ramsay Bowden, David A. Morales-Juarez, … Stephen P. Jackson·eLifePeer-reviewed·May 22, 2020
- Inhibition of p53 improves CRISPR/Cas-mediated precision genome editing
Emma Maria Haapaniemi, Sandeep Kumar Botla, … Jussi Taipale·Nature MedicinePeer-reviewed·Jun 8, 2018
- CRISPR prime editing for unconstrained correction of oncogenic KRAS variants